• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    InMode Reports Second Quarter 2025 Financial Results: Quarterly Revenue of $95.6 Million, 80% Gross Margins

    7/30/25 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $INMD alert in real time by email

    YOKNEAM, Israel, July 30, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2025.

    InMode Ltd. Logo

    Second Quarter 2025 Highlights:

    • Quarterly GAAP revenues of $95.6 million, compared to $86.4 million in the second quarter of 2024.
    • Quarterly revenues from consumables and service of $19.8 million, a decrease of 6% compared to the second quarter of 2024.
    • GAAP operating income of $22.9 million, *non-GAAP operating income of $26.3 million.
    • Total cash position of $510.7 million as of June 30, 2025, including cash and cash equivalents, marketable securities and short-term bank deposits.

    U.S. GAAP Results

    (U.S. dollars in thousands, except for per share data)



       Q2 2025

    Q2 2024

    Revenues

    $95,602

    $86,449

    Gross Margins

    80 %

    80 %

    Net Income

    $26,742

    $23,818

    Earnings per Diluted Share

    $0.42

    $0.28

    *Non-GAAP Results

    (U.S. dollars in thousands, except for per share data)



      Q2 2025

    Q2 2024

    Gross Margins

    80 %

    81 %

    Net Income

    $30,139

    $28,976

    Earnings per Diluted Share

    $0.47

    $0.34

    *Please refer to "Use of Non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation and related tax adjustments.

    Management Comments

    "The second quarter reflects the broader trends we've seen in recent months, with persistent external headwinds, including ongoing macroeconomic uncertainty and a more cautious consumer behavior," said Moshe Mizrahy, Chief Executive Officer of InMode. "While these factors have impacted our results, we remain disciplined in our execution and committed to investing in the capabilities and growth drivers that will enable us to emerge stronger and deliver sustainable long-term value.

    "Although broader economic challenges in the U.S. impacted our overall performance this quarter, our international business provided a certain offset. Once again, sales generated from Europe reached a record high in the second quarter," Mizrahy concluded.

    Yair Malca, Chief Financial Officer of InMode, added, "Our strong balance sheet is a key asset in these uncertain times, giving us the flexibility to retain top talent, expand globally, and continue leading the industry with cutting-edge technologies. Finally, assuming U.S. tariffs remain at their current level of 10%, we expect gross margins to be impacted by approximately 2% to 3%. We continue to evaluate options to mitigate the effects of these tariffs," Malca concluded.

    Second Quarter 2025 Financial Results

    Total revenues for the second quarter of 2025 were $95.6 million.  In the second quarter of 2024, revenues were $86.4 million, excluding $16.2 million in pre-orders for new platforms which had not yet been delivered by quarter-end. 

    GAAP gross margin for the second quarter remained steady at 80%, consistent with the second quarter of 2024. *On a non-GAAP basis, gross margin was 80%, compared to 81% last year.

    GAAP operating margin for the second quarter of 2025 was 24%, compared to 21% in the second quarter of 2024. *Non-GAAP operating margin for the second quarter of 2025 was 28% compared to 27% for the second quarter of 2024.

    InMode reported GAAP net income of $26.7 million, or $0.42 per diluted share, in the second quarter of 2025, compared to $23.8 million, or $0.28 per diluted share, in the second quarter of 2024. On a *non-GAAP basis, InMode reported net income of $30.1 million, or $0.47 per diluted share, in the second quarter of 2025, compared to $29.0 million, or $0.34 per diluted share, in the second quarter of 2024.

    As of June 30, 2025, InMode had cash and cash equivalents, marketable securities and short-term bank deposits of $510.7 million.

    2025 Financial Outlook

    Management provided an outlook for the full year of 2025 ending December 31, 2025. Based on our current estimates, management expects:

    • Revenues between $365 to $375 million, compared to prior guidance of $395 million to $405 million
    • *Non-GAAP gross margin remains the same as in previous guidance between 78% and 80%
    • *Non-GAAP income from operations to be between $93 million and $98 million, compared to previous guidance of $101 million to $106 million
    • *Non-GAAP earnings per diluted share between $1.55 to $1.59, compared to previous guidance of $1.64 to $1.68

    This outlook is not a guarantee of future performance, and stockholders should not rely on such forward-looking statements. See "Forward-Looking Statements" for additional information.

    *Please refer to "Use of Non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation and related tax adjustments.

    The Current Situation in Israel

    Regarding the current situation in Israel, the conflict in the region remains volatile. A ceasefire between Israel and Hamas began in January 2025 but collapsed in March. On June 13, Israel launched a pre-emptive strike on Iran, prompting retaliatory missile and drone attacks. A ceasefire between Israel and Iran was reached on June 23, though its durability remains uncertain. The scope and severity of ongoing conflicts in Gaza, Northern Israel, Lebanon, Iran, and the broader region are unpredictable and could escalate further. To date, our operations have not been materially affected. We continue to monitor political and military developments closely and examine the consequences for our operations and assets. 

    Use of Non-GAAP Financial Measures

    In addition to InMode's operating results presented in accordance with GAAP, this release contains certain non-GAAP financial measures including non-GAAP net income, non-GAAP earnings per diluted share, non-GAAP operating margin. Because these measures are used in InMode's internal analysis of financial and operating performance, management believes they provide investors with greater transparency of its view of InMode's economic performance. Management also believes the presentation of these measures, when analyzed in conjunction with InMode's GAAP operating results, allows investors to more effectively evaluate and compare InMode's performance to that of its peers, although InMode's presentation of its non-GAAP measures may not be strictly comparable to the similarly titled measures of other companies. Schedules reconciling each of these non-GAAP financial measures are provided as a supplement to this release.

    Conference Call Information

    Mr. Moshe Mizrahy, Chief Executive Officer, Dr. Michael Kreindel, Co-Founder and Chief Technology Officer, Mr. Yair Malca, Chief Financial Officer will host a conference call today, July 30, 2025, at 8:30 a.m. Eastern Time to discuss the second quarter 2025 financial results.

    The Company encourages participants to pre-register for the conference call using the following link: 

    https://dpregister.com/sreg/10201337/ff895a1432.

    Callers will receive a unique dial-in number upon registration, which enables immediate access to the call. Participants may pre-register at any time, including up to and after the call start time.

    For callers who opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call 10 minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number.

    U.S. Toll-Free Dial-in Number: 1-833-316-0562

    Israel Toll- Free Dial-in Number: 1-80-921-2373

    International Dial-in Number: 1-412-317-5736

    Webcast URL: https://event.choruscall.com/mediaframe/webcast.html?webcastid=LXTC7h0

    At:

    8:30 a.m. Eastern Time

    5:30 a.m. Pacific Time

    The conference call will also be webcast live from a link on InMode's website at https://inmodemd.com/investors/events-presentations/. A replay of the conference call will be available from July 30, 2025, at 12 p.m. Eastern Time to August 13, 2025, at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers: 

    Replay Dial-in U.S TOLL-FREE: 1-877-344-752

    Replay Dial-in Canada TOLL-FREE: 1-855-669-9658

    Replay Dial-in TOLL/INTERNATIONAL: 1-412-317-0088

    Replay Pin Number: 4085483

    To access the replay using an international dial-in number, please select the link below:

    https://services.choruscall.com/ccforms/replay.html

    A replay of the conference call will also be available for 90 days on InMode's website at https://inmodemd.com/investors/.

    About InMode

    InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.

    Forward-Looking Statements

    The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the 2025 revenue projection described above. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 4, 2025, and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

    Company Contact:

    Yair Malca

    Chief Financial Officer

    Phone: (949) 305-0108

    Email: [email protected]

    Investor Relations Contact:

    Miri Segal

    MS-IR LLC

    Email: [email protected]

     

    INMODE LTD.

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)





    Three months ended

    June 30,

    Six months ended

    June 30,



    2025

    2024

    2025

    2024



    REVENUES

    95,602

    86,449

    173,476

    166,733



    COST OF REVENUES

    19,152

    17,116

    36,115

    33,481



    GROSS PROFIT

    76,450

    69,333

    137,361

    133,252



    OPERATING EXPENSES:











    Research and development

    3,372

    3,698

    6,267

    7,216



    Sales and marketing

    47,474

    45,055

    87,201

    84,850



    General and administrative

    2,723

    2,266

    5,394

    4,780



    TOTAL OPERATING EXPENSES

    53,569

    51,019

    98,862

    96,846



    OPERATIONS INCOME

    22,881

    18,314

    38,499

    36,406



    Finance income, net

    8,062

    8,690

    14,921

    16,674



    INCOME BEFORE INCOME TAXES

    30,943

    27,004

    53,420

    53,080



    INCOME TAXES

    4,201

    3,186

    8,477

    5,566



    NET INCOME

    26,742

    23,818

    44,943

    47,514















    EARNINGS PER SHARE:











    Basic

    0.42

    0.28

    0.68

    0.56



    Diluted

    0.42

    0.28

    0.68

    0.55



    WEIGHTED AVERAGE NUMBER OF SHARES

    OUTSTANDING USED IN COMPUTATION OF

    EARNINGS PER SHARE (in thousands)











    Basic

    63,252

    83,878

    65,982

    84,205



    Diluted

    63,637

    85,890

    66,540

    86,520



     

    INMODE LTD.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)





    June 30,

    2025

    December 31,

    2024

    Assets





    CURRENT ASSETS:





    Cash and cash equivalents

    216,237

    155,329

    Marketable securities

    183,388

    267,688

    Short-term bank deposits

    111,058

    173,455

    Accounts receivable, net of allowance for credit losses

    35,654

    36,335

    Prepaid expense and other receivables

    24,334

    22,097

    Inventories

    68,110

    59,548

             TOTAL CURRENT ASSETS

    638,781

    714,452

        NON-CURRENT ASSETS:





    Accounts receivable, net of allowance for credit losses

    2,545

    3,176

    Deferred income tax asset

    54,763

    56,285

    Operating lease right-of-use assets

    9,299

    8,732

    Property and equipment, net

    2,260

    2,322

    Other investments

    700

    700

    TOTAL NON-CURRENT ASSETS

    69,567

    71,215

    TOTAL ASSETS

    708,348

    785,667

    Liabilities and shareholders' equity





    CURRENT LIABILITIES:





    Accounts payable

    17,482

    13,782

    Contract liabilities

    12,996

    16,755

    Other liabilities

    36,056

    39,314

    TOTAL CURRENT LIABILITIES

    66,534

    69,851

        NON-CURRENT LIABILITIES:





    Contract liabilities

    3,355

    3,336

    Other liabilities

    3,919

    3,356

    Operating lease liabilities

    6,103

    5,311

    TOTAL NON-CURRENT LIABILITIES

    13,377

    12,003

    TOTAL LIABILITIES

    79,911

    81,854







    TOTAL SHAREHOLDERS' EQUITY

    628,437

    703,813

    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

    708,348

    785,667

     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)





    Three months ended

    June 30,

    Six months ended

    June 30,



    2025

    2024

    2025

    2024



    CASH FLOWS FROM OPERATING ACTIVITIES:











    Net income

    26,742

    23,818

    44,943

    47,514



    Adjustments required to reconcile net income to net cash provided by operating activities:











    Depreciation and amortization

    191

    177

    365

    342



    Share-based compensation expenses

    3,418

    5,158

    5,936

    9,141



    Change in allowance for credit losses of trade receivable

    147

    97

    53

    284



    Loss on marketable securities, net

    5

    112

    3

    141



    Finance income, net

    (313)

    (5,040)

    (1,887)

    (9,797)



    Deferred income taxes

    566

    (56)

    1,462

    (93)



    Changes in operating assets and liabilities:











    Decrease (increase) in accounts receivable

    (3,285)

    (4,814)

    1,259

    4,494



    Decrease (increase) in other receivables

    1,276

    (4,048)

    (2,256)

    (6,717)



    Increase in inventories

    (4,329)

    (1,025)

    (8,562)

    (7,532)



    Increase in accounts payable

    2,430

    2,325

    3,700

    1,582



    Increase (decrease) in other liabilities

    127

    2,241

    (3,160)

    (5,562)



    Increase (decrease) in contract liabilities (current and non-current)

    (2,903)

    23,114

    (3,740)

    32,376



    Net cash provided by operating activities

    24,072

    42,059

    38,116

    66,173



    CASH FLOWS FROM INVESTING ACTIVITIES:











       Investment in short-term deposits

    (25,000)

    (55,000)

    (25,000)

    (86,297)



       Proceeds from short-term deposits

    55,000

    13,500

    86,297

    13,500



       Purchase of fixed assets

    (219)

    (246)

    (304)

    (358)



       Purchase of marketable securities

    -

    (64,129)

    (20,877)

    (185,693)



       Proceeds from sale of marketable securities

    -

    33,910

    3,003

    47,375



       Proceeds from maturity of marketable securities

    41,875

    89,690

    104,022

    181,808



    Net cash provided by (used in) investing activities

    71,656

    17,725

    147,141

    (29,665)



    CASH FLOWS FROM FINANCING ACTIVITIES:











      Repurchase of ordinary shares

    (27,484)

    (88,980)

    (127,444)

    (88,980)



           Exercise of options

    505

    395

    999

    629



    Net cash used in financing activities

    (26,979)

    (88,585)

    (126,445)

    (88,351)



    EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS

    1,540

    (132)

    2,096

    (571)



    NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

    70,289

    (28,933)

    60,908

    (52,414)















    CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD

    145,948

    120,930

    155,329

    144,411



    CASH AND CASH EQUIVALENTS AT END OF PERIOD

    216,237

    91,997

    216,237

    91,997



     

     



    INMODE LTD.

    CONDENSED CONSOLIDATED FINANCIAL HIGHLIGHTS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)





    Three months ended June 30,

    Six months ended June 30,

    2025

    2024

    2025

    2024

    Revenues by Category:



































    Capital Equipment revenues - United States

    40,653

    42 %

    34,799

    41 %

    70,195

    40 %

    65,658

    39 %

    Capital Equipment revenues - International

    35,133

    37 %

    30,606

    35 %

    63,266

    37 %

    57,529

    35 %

    Total Capital Equipment revenues

    75,786

    79 %

    65,405

    76 %

    133,461

    77 %

    123,187

    74 %

    Consumables and service revenues

    19,816

    21 %

    21,044

    24 %

    40,015

    23 %

    43,546

    26 %

    Total Revenue

    95,602

    100 %

    86,449

    100 %

    173,476

    100 %

    166,733

    100 %



































































































    Three months ended June 30,

    Six months ended June 30,

    2025

    2024

    2025

    2024



    %

    %

    %

    %



    United States

    International

    Total

    United States

    International

    Total

    United States

    International

    Total

    United States

    International

    Total

    Revenues by

    Technology:

























    Minimal-Invasive

    73

    82

    78

    85

    86

    87

    82

    81

    81

    87

    84

    86

    Hands-Free

    4

    2

    3

    11

    4

    7

    3

    2

    3

    9

    3

    6

    Non-Invasive

    23

    16

    19

    4

    10

    6

    15

    17

    16

    4

    13

    8



    100

    100

    100

    100

    100

    100

    100

    100

    100

    100

    100

    100

     

    INMODE LTD.

    RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF

     INCOME TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF INCOME 

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)













    Three months ended June 30, 2025

    Three months ended June 30, 2024



    GAAP

    Share Based

    Compensation

    Non-GAAP

    GAAP

    Share Based

    Compensation

    Non-GAAP



    REVENUES

    95,602

    -

    95,602

    86,449

    -

    86,449



    COST OF REVENUES

    19,152

    (334)

    18,818

    17,116

    (471)

    16,645



    GROSS PROFIT

    76,450

    334

    76,784

    69,333

    471

    69,804



    OPERATING EXPENSES:















    Research and development

    3,372

    (287)

    3,085

    3,698

    (559)

    3,139



    Sales and marketing

    47,474

    (2,529)

    44,945

    45,055

    (3,824)

    41,231



    General and administrative

    2,723

    (268)

    2,455

    2,266

    (304)

    1,962



    TOTAL OPERATING

    EXPENSES

    53,569

    (3,084)

    50,485

    51,019

    (4,687)

    46,332



    OPERATIONS INCOME

    22,881

    3,418

    26,299

    18,314

    5,158

    23,472



    Finance income, net

    8,062

    -

    8,062

    8,690

    -

    8,690



    INCOME BEFORE INCOME TAXES

    30,943

    3,418

    34,361

    27,004

    5,158

    32,162



    INCOME TAXES

    4,201

    21

    4,222

    3,186

    -

    3,186



    NET INCOME

    26,742

    3,397

    30,139

    23,818

    5,158

    28,976



















    EARNINGS PER SHARE:















    Basic

    0.42



    0.48

    0.28



    0.35



    Diluted

    0.42



    0.47

    0.28



    0.34



    WEIGHTED AVERAGE NUMBER OF

    SHARES OUTSTANDING USED IN

    COMPUTATION OF EARNINGS PER

    SHARE (in thousands)















    Basic

    63,252



    63,252

    83,878



    83,878



    Diluted

    63,637



    64,537

    85,890



    85,900





    Six months ended June 30, 2025

    Six months ended June 30, 2024

    GAAP

    Share Based

    Compensation

    Non-GAAP

    GAAP

    Share Based

    Compensation

    Non-GAAP

    REVENUES

    173,476

    -

    173,476

    166,733

    -

    166,733

    COST OF REVENUES

    36,115

    (644)

    35,471

    33,481

    (880)

    32,601

    GROSS PROFIT

    137,361

    644

    138,005

    133,252

    880

    134,132

    OPERATING EXPENSES:













    Research and development

    6,267

    (509)

    5,758

    7,216

    (987)

    6,229

    Sales and marketing

    87,201

    (4,292)

    82,909

    84,850

    (6,707)

    78,143

    General and administrative

    5,394

    (491)

    4,903

    4,780

    (567)

    4,213

    TOTAL OPERATING

    EXPENSES

    98,862

    (5,292)

    93,570

    96,846

    (8,261)

    88,585

    OPERATIONS INCOME

    38,499

    5,936

    44,435

    36,406

    9,141

    45,547

    Finance income, net

    14,921

    -

    14,921

    16,674

    -

    16,674

    INCOME BEFORE INCOME TAXES

    53,420

    5,936

    59,356

    53,080

    9,141

    62,221

    INCOME TAXES

    8,477

    (655)

    7,822

    5,566

    -

    5,566

    NET INCOME

    44,943

    6,591

    51,534

    47,514

    9,141

    56,655















    EARNINGS PER

    SHARE:













    Basic

    0.68



    0.78

    0.56



    0.67

    Diluted

    0.68



    0.77

    0.55



    0.65

    WEIGHTED AVERAGE

    NUMBER OF SHARES

    OUTSTANDING USED IN

    COMPUTATION OF

    EARNINGS PER SHARE (in

    thousands)













    Basic

    65,982



    65,982

    84,205



    84,205

    Diluted

    66,540



    67,052

    86,520



    86,531

     

    Logo - https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg

    Cision View original content:https://www.prnewswire.com/news-releases/inmode-reports-second-quarter-2025-financial-results-quarterly-revenue-of-95-6-million-80-gross-margins-302515137.html

    SOURCE InMode Ltd.

    Get the next $INMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INMD

    DatePrice TargetRatingAnalyst
    4/29/2025Buy → Neutral
    BTIG Research
    4/28/2025$22.00 → $16.00Outperform → Neutral
    Robert W. Baird
    10/17/2024$25.00Buy
    BTIG Research
    7/23/2024$21.00 → $19.00Buy → Hold
    Jefferies
    11/3/2023$52.00 → $24.00Buy → Neutral
    UBS
    10/13/2023$55.00 → $22.00Buy → Hold
    Canaccord Genuity
    3/29/2023$40.00Buy
    UBS
    2/17/2023Buy → Hold
    Needham
    More analyst ratings

    $INMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins

    YOKNEAM, Israel, Nov. 5, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights: Quarterly GAAP revenues of $93.2 million, compared to $130.2 million in the third quarter of 2024, which included $31.9 million of pre-order sales.Quarterly revenues from consumables and service of $19.9 million, an increase of 26% compared to the third quarter of 2024.GAAP operating income of $20.9 million. *Non-GAAP operating income was $23.6 million.Total cash position of $532.3 million as of September 30, 2025, incl

    11/5/25 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Appoints Michael Dennison as President of North America

    IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America.  Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar

    11/3/25 8:05:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Participate in Upcoming Investor Conferences

    YOKNEAM, Israel, Oct. 30, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation in the following investor conferences in November: UBS Global Healthcare Conference Presenter: Yair Malca, Chief Financial Officer Format: In-person one-on-one meetings Location: Palm Beach Gardens, FL When: Monday, November 10 Jefferies Global Healthcare Conference Presenter: Moshe Mizrahy, Chief Executive Officer Format: In-person fireside chat moderated by Matt Taylor, Senior Equity Analyst, and one-on-one meetings Location: London, U.K. When: Tuesday, November 18, Fireside Chat at 4:00 pm GMT A live webcast of the prese

    10/30/25 8:30:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    InMode downgraded by BTIG Research

    BTIG Research downgraded InMode from Buy to Neutral

    4/29/25 8:06:22 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously

    4/28/25 1:56:11 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on InMode with a new price target

    BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00

    10/17/24 7:41:34 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    SEC Filings

    View All

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    11/5/25 7:00:08 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    9/18/25 7:30:09 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    7/30/25 7:01:14 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Leadership Updates

    Live Leadership Updates

    View All

    InMode Appoints Michael Dennison as President of North America

    IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America.  Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar

    11/3/25 8:05:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Financials

    Live finance-specific insights

    View All

    InMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins

    YOKNEAM, Israel, Nov. 5, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights: Quarterly GAAP revenues of $93.2 million, compared to $130.2 million in the third quarter of 2024, which included $31.9 million of pre-order sales.Quarterly revenues from consumables and service of $19.9 million, an increase of 26% compared to the third quarter of 2024.GAAP operating income of $20.9 million. *Non-GAAP operating income was $23.6 million.Total cash position of $532.3 million as of September 30, 2025, incl

    11/5/25 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Report Third Quarter 2025 Financial Results and Hold Conference Call on November 5, Expects Q3 Revenue Between $92.5M-$93.0M, Reiterates FY 2025 Guidance Between $365M-$375M

    Conference call to be held on Wednesday, November 5, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 9, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter 2025 before the Nasdaq market opens on Wednesday, November 5, 2025. InMode is currently finalizing its financial results for the third quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and other developments that may aris

    10/9/25 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Return Capital to the Shareholders

    Believes the Board Should Approve and Execute a 10% Buyback in Q4 2025 and Another 10% Buyback in Q1 2026 Maintains Board Has Legal and Fiduciary Duty to Act in Best Interests of Shareholders  MIAMI, Sept. 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to return capital to shareholders.  The letter can be downloaded here The full text of the letter follows: September 9th, 2025 To the Board Members of InMode: In

    9/9/25 8:15:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:31:18 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:25:40 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by InMode Ltd.

    SC 13G - InMode Ltd. (0001742692) (Subject)

    2/6/24 9:36:39 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care